Cargando…

A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing

OBJECTIVES: This study investigated and quantified risk factors of dose escalation, as an indication of drug misuse and dependency of benzodiazepines and congeners, among presumably drug naïve patients in the Norwegian drug prescription database, observed over 3 years. DESIGN: Observational study. S...

Descripción completa

Detalles Bibliográficos
Autores principales: Tvete, Ingunn Fride, Bjørner, Trine, Aursnes, Ivar Andreas, Skomedal, Tor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796278/
https://www.ncbi.nlm.nih.gov/pubmed/24097305
http://dx.doi.org/10.1136/bmjopen-2013-003296
_version_ 1782287452920086528
author Tvete, Ingunn Fride
Bjørner, Trine
Aursnes, Ivar Andreas
Skomedal, Tor
author_facet Tvete, Ingunn Fride
Bjørner, Trine
Aursnes, Ivar Andreas
Skomedal, Tor
author_sort Tvete, Ingunn Fride
collection PubMed
description OBJECTIVES: This study investigated and quantified risk factors of dose escalation, as an indication of drug misuse and dependency of benzodiazepines and congeners, among presumably drug naïve patients in the Norwegian drug prescription database, observed over 3 years. DESIGN: Observational study. SETTING: Prescription database study. PARTICIPANTS: We defined an excessive user as one redeeming more than two defined daily doses per day in 3 months. PRIMARY AND SECONDARY OUTCOME MEASURES: We examined the risk of excessive use over time and the effect of risk factors through multistate logistic regression and scenarios. RESULTS: Most of the 81 945 patients had zopiclone or zolpidem as the initial drug (63.8%), followed by diazepam (25.3%), oxazepam (6.1%), nitrazepam/flunitrazepam (2.9%), hydroxyzine/buspirone (1.6%) and alprazolam (0.3%). At any time 23% redeemed prescriptions, about 34% did not redeem any prescriptions beyond any 3-month period and 0.9% ended up as excessive users. Patients previously using drugs, such as opioids, antialcohol or smoke cessation treatment, had a higher risk to become excessive users compared to patients who had not. Patients whose first prescription was for oxazepam or nitrazepam/flunitrazepam had a higher risk of becoming an excessive user compared to those who started with diazepam. A specialist in general practice as the first-time prescriber was associated with a lower risk compared to doctors without specialty. CONCLUSIONS: Most benzodiazepine use occurred according to guidelines. Still, some experienced dose escalation over time, and risk factors were previous use of other psychotropic drugs, long time use, choice of first-time drug and prescriber's specialty. This could incite doctors to have a cessation plan when issuing first-time prescriptions.
format Online
Article
Text
id pubmed-3796278
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-37962782013-10-15 A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing Tvete, Ingunn Fride Bjørner, Trine Aursnes, Ivar Andreas Skomedal, Tor BMJ Open Addiction OBJECTIVES: This study investigated and quantified risk factors of dose escalation, as an indication of drug misuse and dependency of benzodiazepines and congeners, among presumably drug naïve patients in the Norwegian drug prescription database, observed over 3 years. DESIGN: Observational study. SETTING: Prescription database study. PARTICIPANTS: We defined an excessive user as one redeeming more than two defined daily doses per day in 3 months. PRIMARY AND SECONDARY OUTCOME MEASURES: We examined the risk of excessive use over time and the effect of risk factors through multistate logistic regression and scenarios. RESULTS: Most of the 81 945 patients had zopiclone or zolpidem as the initial drug (63.8%), followed by diazepam (25.3%), oxazepam (6.1%), nitrazepam/flunitrazepam (2.9%), hydroxyzine/buspirone (1.6%) and alprazolam (0.3%). At any time 23% redeemed prescriptions, about 34% did not redeem any prescriptions beyond any 3-month period and 0.9% ended up as excessive users. Patients previously using drugs, such as opioids, antialcohol or smoke cessation treatment, had a higher risk to become excessive users compared to patients who had not. Patients whose first prescription was for oxazepam or nitrazepam/flunitrazepam had a higher risk of becoming an excessive user compared to those who started with diazepam. A specialist in general practice as the first-time prescriber was associated with a lower risk compared to doctors without specialty. CONCLUSIONS: Most benzodiazepine use occurred according to guidelines. Still, some experienced dose escalation over time, and risk factors were previous use of other psychotropic drugs, long time use, choice of first-time drug and prescriber's specialty. This could incite doctors to have a cessation plan when issuing first-time prescriptions. BMJ Publishing Group 2013-10-04 /pmc/articles/PMC3796278/ /pubmed/24097305 http://dx.doi.org/10.1136/bmjopen-2013-003296 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Addiction
Tvete, Ingunn Fride
Bjørner, Trine
Aursnes, Ivar Andreas
Skomedal, Tor
A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing
title A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing
title_full A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing
title_fullStr A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing
title_full_unstemmed A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing
title_short A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing
title_sort 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing
topic Addiction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796278/
https://www.ncbi.nlm.nih.gov/pubmed/24097305
http://dx.doi.org/10.1136/bmjopen-2013-003296
work_keys_str_mv AT tveteingunnfride a3yearsurveyquantifyingtheriskofdoseescalationofbenzodiazepinesandcongenerstoidentifyriskfactorstoaiddoctorstomorerationaleprescribing
AT bjørnertrine a3yearsurveyquantifyingtheriskofdoseescalationofbenzodiazepinesandcongenerstoidentifyriskfactorstoaiddoctorstomorerationaleprescribing
AT aursnesivarandreas a3yearsurveyquantifyingtheriskofdoseescalationofbenzodiazepinesandcongenerstoidentifyriskfactorstoaiddoctorstomorerationaleprescribing
AT skomedaltor a3yearsurveyquantifyingtheriskofdoseescalationofbenzodiazepinesandcongenerstoidentifyriskfactorstoaiddoctorstomorerationaleprescribing
AT tveteingunnfride 3yearsurveyquantifyingtheriskofdoseescalationofbenzodiazepinesandcongenerstoidentifyriskfactorstoaiddoctorstomorerationaleprescribing
AT bjørnertrine 3yearsurveyquantifyingtheriskofdoseescalationofbenzodiazepinesandcongenerstoidentifyriskfactorstoaiddoctorstomorerationaleprescribing
AT aursnesivarandreas 3yearsurveyquantifyingtheriskofdoseescalationofbenzodiazepinesandcongenerstoidentifyriskfactorstoaiddoctorstomorerationaleprescribing
AT skomedaltor 3yearsurveyquantifyingtheriskofdoseescalationofbenzodiazepinesandcongenerstoidentifyriskfactorstoaiddoctorstomorerationaleprescribing